Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium

Holly R. Harris & Lynn Rosenberg et al. · 2022-06-30

Abstract

Black women diagnosed with epithelial ovarian cancer have poorer survival compared to white women. Factors that contribute to this disparity, aside from socioeconomic status and guideline‐adherent treatment, have not yet been clearly identified. We examined data from the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium which harmonized data on 1074 Black women and 3263 white women with ovarian cancer from seven US studies. We selected potential mediators and confounders by examining associations between each variable with race and survival. We then conducted a sequential mediation analysis using an imputation method to estimate total, direct, and indirect effects of race on ovarian cancer survival. Black women had worse survival than white women (HR = 1.30; 95% CI 1.16‐1.47) during study follow‐up; 67.9% of Black women and 69.8% of white women died. In our final model, mediators of this disparity include college education, nulliparity, smoking status, body mass index, diabetes, diabetes/race interaction, postmenopausal hormone (PMH) therapy duration, PMH duration/race interaction, PMH duration/age interaction, histotype, and stage. These mediators explained 48.8% (SE = 12.1%) of the overall disparity; histotype/stage and PMH duration accounted for the largest fraction. In summary, nearly half of the disparity in ovarian cancer survival between Black and white women in the OCWAA consortium is explained by education, lifestyle factors, diabetes, PMH use, and tumor characteristics. Our findings suggest that several potentially modifiable factors play a role. Further research to uncover additional mediators, incorporate data on social determinants of health, and identify potential avenues of intervention to reduce this disparity is urgently needed.

Funding
Collaborative Genetic Study of Ovarian Cancer RiskA Follow-up Study for Causes of Illness in Black WomenCancer Research Training and Education CoordinationNHLBI NIH HHS Grant HHSN268201600004CThe Molecular Epidemiology Of Ovarian CancerNHLBI NIH HHS Grant HHSN268201600001CExploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortiumUnderstanding Population Differences in Cancer: The MEC StudyAn assessment of whether aspirin and/or vitamin D improves breast cancer outcomes in Black women and the modifying effect of genetic variantsWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2Women's Health Initiative Cancer Survivor CohortNHLBI NIH HHS Grant HHSN268201600002CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600018CA Follow-up Study for Causes of Cancer in Black WomenNHLBI NIH HHS Grant HHSN268201600003CHormone Therapy and Risk of Ovarian CancerEpidemiology of Ovarian Cancer in African-American WomenThe National Cancer Institute Grant P30‐CA014089The National Cancer Institute Grant R01‐CA076016National Cancer Institute Grant R01‐CA142081The National Cancer Institute Grant R01‐CA17054The National Cancer Institute Grant R01‐CA58598National Cancer Institute Grant U01‐CA164973National Heart, Lung, and Blood Grant HHSN268201600001CNational Heart, Lung, and Blood Grant HHSN268201600002CNational Heart, Lung, and Blood Grant HHSN268201600003CNational Heart, Lung, and Blood Grant HHSN268201600004CNational Heart, Lung, and Blood Grant HHSN268201600018CNational Heart, Lung, and Blood Institute Grant NHLBI‐75N92021D00002National Heart, Lung, and Blood Institute Grant NHLBI‐CSB‐WH‐2016‐01‐CMNational Institutes of Health Grant K01‐CA212056National Institutes of Health Grant R01‐CA058420National Institutes of Health Grant R01‐CA207260National Institutes of Health Grant R01‐CA61093National Institutes of Health Grant U01‐CA164974National Institutes of Health Grant UM1‐CA164974National Institutes of Health Grant UM1‐CA173642‐05

NCI NIH HHS

R01 CA058598

NCI NIH HHS

R01 CA058420

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R01 CA076016

NCI NIH HHS

R01 CA207260

NCI NIH HHS

U01 CA164973

NCI NIH HHS

K01 CA212056

NCI NIH HHS

UM1 CA173642

NCI NIH HHS

U01 CA164974

NCI NIH HHS

UM1 CA164974

NCI NIH HHS

P01 CA017054

NCI NIH HHS

R01 CA142081